Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance

The emergence of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) propelled EGFR-mutated patients of non-small cell lung cancer (NSCLC) into the era of precision medicine. Third-generation targeted therapies, such as osimertinib, can specifically target the T790M mutation and effectively overcome resistance to previous treatments, significantly prolonging progression-free survival in patients. Despite its remarkable clinical efficacy and manageable safety profile, it is still not immune to the development of resistance. Therefore, overcoming resistance and providing new treatment strategies for advanced NSCLC patients harboring EGFR mutations after osimertinib resistance are priorities that need to be considered. New-generation EGFR-TKIs or combination therapeutic strategies hold promise to address resistance. In addition, with the development of genomics and molecular diagnostic technologies, several drugs with novel mechanisms of action, such as antibody-drug conjugates and bispecific antibodies, have shown promising clinical response rates and favorable safety profiles in several clinical and experimental studies. This review aims to more systematically indicate the mechanisms of EGFR-TKI resistance and summarize the new strategies available and novel drugs under investigation for NSCLC patients harboring EGFR mutations after TKI resistance to extend their survival and improve quality of life.